WuXi Biologics (Cayman) Inc.

WuXi Biologics is a prominent global Contract Research, Development and Manufacturing Organization (CRDMO) that specializes in biologics drug development and manufacturing. Founded in 2010 in Wuxi, China, the company has grown significantly, going public in 2017 and achieving a market capitalization of approximately $14.5 billion as of October 2023. The company offers a comprehensive range of services throughout the drug development lifecycle, including early-stage discovery, process development, commercial manufacturing, and biologics testing. WuXi Biologics operates 18 manufacturing sites worldwide, with facilities in China, the United States, Ireland, Germany, and Singapore. The company emphasizes quality, speed, and cost-effectiveness in delivering biologics solutions and is committed to advancing innovation in the biopharmaceutical industry. With a workforce of over 5,000 employees, WuXi Biologics plays a vital role in supporting the development of new therapies.